KARBE FRANK
SEC CIK 1276700 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | Dir | 91.6K | $99.1K | — | 6 | 2023-05-25 | 2026-05-19 |
Most active insiders at PHAT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Breedlove Robert Charles | Principal Accounting Off | — | $7,079 |
| 2 | Narula Sanjeev | Chief Financial, Bus. Off | — | — |
| 3 | Parikh Asit | Dir | — | — |
| 4 | Stenhouse Mark | Dir | — | — |
| 5 | Basta Steven L | Pres, CEO, Dir | — | — |
| 6 | Schroeder Theodore R | Dir | — | — |
| 7 | Topper James N | Dir, 10% | — | — |
| 8 | Cook Anne Marie | Chief Legal Off, Corp. Sec | — | — |
| 9 | KARBE FRANK | Dir | — | — |
| 10 | COLA MICHAEL F | Dir | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-21 16:30 | 2026-05-19 | PHAT | Phathom Pharmaceuticals, Inc. | KARBE FRANK | Dir | A - Grant | $0.00 | +24.1K | 91.6K | +36% | $0 | |
| D | 2025-06-05 | 2025-06-03 | PHAT | Phathom Pharmaceuticals, Inc. | KARBE FRANK | Dir | A - Grant | $0.00 | +10.5K | 67.5K | +18% | $0 |
| 2024-12-16 | 2024-12-13 | PHAT | Phathom Pharmaceuticals, Inc. | KARBE FRANK | Dir | P - Purchase | $7.93 | +12.5K | 57.0K | +28% | +$99.1K | |
| 2024-05-31 | 2024-05-29 | PHAT | Phathom Pharmaceuticals, Inc. | KARBE FRANK | Dir | A - Grant | $10.16 | +25.0K | 44.5K | +128% | +$254.0K | |
| D | 2024-05-24 | 2024-05-23 | PHAT | Phathom Pharmaceuticals, Inc. | KARBE FRANK | Dir | A - Grant | $0.00 | +10.5K | 19.5K | +117% | $0 |
| D | 2023-05-30 | 2023-05-25 | PHAT | Phathom Pharmaceuticals, Inc. | KARBE FRANK | Dir | A - Grant | $0.00 | +9,000 | 9,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations